Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
腾讯网1 天
Vertex(VERX.US)非成瘾性止痛药遭遇“安慰剂效应” 分析师称其带来挫折
Vertex的药物suzetrigine被誉为一项科学突破，因为它阻断了一种有助于控制人体神经元活动的钠通道，在不进入大脑的情况下治疗疼痛。这使得它比阿片类药物更不容易上瘾，在截至2024年6月的一年中，阿片类药物导致约7万人因过量服用而死亡。如果获 ...
Cramer’s Mad Dash: Vertex Pharmaceuticals
CNBC’s Jim Cramer delivers his daily Mad Dash. Drones Banned in New Jersey Over 'Imminent Security Threat' Finnair New A350 - ...
Vertex Pharmaceuticals宣布ALYFTREK获得FDA批准
这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。
Vertex Pharmaceuticals Faces Uncertainty with Mixed Phase 2 Trial Results
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday.Pick the best stocks and ...
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...
Vertex股票评级为"市场表现"，因对更广泛的神经病理性疼痛前景持 ...
该股的盘前表现反映了不确定性，下跌12%。考虑到对公司正在进行的糖尿病周围神经病变（DPN）三期试验的潜在影响，这一反应可能被认为是适度的。最初，分析师认为LSR试验结果对DPN试验的影响有限，暗示可能存在买入机会。然而，在更详细地回顾了过去的DPN试验后，伯恩斯坦决定保持谨慎态度。
Business Insider1 天
Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
Barclays lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $418 from $509 and keeps an Equal Weight rating on the shares. The firm says the Phase 2 painful lumbosacral radiculopathy ...
Benzinga.com2 天
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Post-hoc analysis revealed variability in placebo response, highlighting trial design challenges for future studies. On ...